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Ourmissionwas to develop evidence-based guidelines for the
prevention and treatment of perioperative/postoperative
atrial fibrillation and flutter (POAF) for thoracic surgical
procedures. Sixteen experts were invited by the American
Association for Thoracic Surgery (AATS) leadership: 7
cardiologists and electrophysiology specialists, 3 inten-
sivists/anesthesiologists, 1 clinical pharmacist, joined by 5
thoracic and cardiac surgeons who represented AATS (see
Online Data Supplement 1 for the list of members and
Online Data Supplement 2 for the conflict of interest declara-
tion online). Members were tasked with making
recommendations based on a review of the literature, with
grading the quality of the evidence supporting the
recommendations, and with assessing the risk-benefit profile
for each recommendation (Table 1). Members were
specifically asked to assess the applicability of the available
evidence to patients undergoing thoracic surgery (detailed
methodology can be found online). All recommendations
were subjected to a vote. Acceptance for the final document
required greater than 75% approval of each of the
recommendations. Subsequently, the recommendations
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College of Medicine of Case Western Reserve University Cleveland Clinic, Cleve-
land, Ohio; Division of Cardiovascular Medicine,c Department of Medicine, Case
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The following recommendations are based on the best
available evidence from thoracic surgery. When evidence
specific to thoracic surgery was not available, we
extrapolated from the cardiac surgical literature. In the
absence of direct evidence, we present the best expert
opinion based on cardiology/cardiac electrophysiology
experience and best practices.
For the development of the guidelines, we followed the
recommendations of The Institute of Medicine (IOM)
2011 Clinical Practice Guidelines We Can Trust: Standards
for Developing Trustworthy Clinical Practice Guidelines;
www.iom.edu/cpgstandards.1 Efforts were made to
minimize repetition of existing guidelines2-4; rather we
focused on new information and advances in diagnosis
and therapy, and present these current guidelines within
the framework of the new IOM recommendations. In
order to meet these standards, most societies (American
Heart Association and AATS included) initiated the
revision2,3 of existing guidelines.AATS Member Survey
Our survey of the AATS members (results presented in
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the areas of prevention, standards for postoperative electro-
cardiography (ECG) monitoring and the use of novel oralof Cardiovascular Medicine,k Department of Medicine, Arrhythmia Service, Van-
derbilt University School of Medicine, Nashville, Tenn; Division of Thoracic Sur-
gery,l Department of Surgery, Brigham and Women’s Hospital and Harvard
Medical School, Boston, Mass; Division of Thoracic Surgery,m Department of Sur-
gery, University of Toronto, Toronto, Ontario, Canada; Memorial Sloan-Kettering
Cancer Center,n Department of Anesthesiology and Critical Care Medicine, New
York, NY; Division of Cardiovascular Medicine,o Department of Medicine, Brig-
ham and Women’s Hospital and Harvard Medical School, Boston, Mass.
Disclosures: See Online Data Supplement 2.
Received for publication June 9, 2014; accepted for publication June 10, 2014.
Address for reprints: Gyorgy Frendl, MD, PhD, Department of Anesthesiology, Peri-
operative and Pain Medicine, Brigham and Women’s Hospital, CWN-L1, 75 Fran-
cis St, Boston, MA 02115 (E-mail: gfrendl@partners.org).
J Thorac Cardiovasc Surg 2014;148:772-91
0022-5223/$36.00
Copyright  2014 by The American Association for Thoracic Surgery
http://dx.doi.org/10.1016/j.jtcvs.2014.06.037
ery c September 2014
Frendl et al Clinical Guidelinesanticoagulants. When asked how the AATS could help
members improve their practices, 29% of respondents rec-
ommended ‘‘initiating studies,’’ whereas 58% recommen-
ded that the AATS ‘‘issue guidelines’’ and promote
uniform practices.Target Audience and Patient Population
These guidelines are intended for all noncardiac
intrathoracic surgeries and esophagectomies, as well as
for patients whose risk factors and comorbidities place
them at intermediate to high risk for POAF independent
of the procedure. In assessing the patient’s risk for
POAF, it must be noted that the risks posed by the
procedure and by patient factors/comorbidities will likely
be additive, if not synergistic. Therefore, these factors
should be evaluated in combination during the preopera-
tive assessment.
The target audience includes not only thoracic surgeons
and anesthesiologists but all providers who participate in
the care of thoracic surgical patients.
The following novel information is included in this 2014
document: (1) standardized definitions for atrial fibrillation
(AF) and (2) recommendations for: (a) ECG monitoring,
(b) postdischarge management, (c) use of the new-class of
novel oral anticoagulants (NOAC); and (d) obtaining
cardiology consultation. In addition, flow diagrams
summarize the strategies for acute and chronic manage-
ment. Specific drug recommendations and dosing tables
are also included.Epidemiology and Mechanisms of POAF
AF, the most common sustained arrhythmia after
pulmonary and esophageal surgery, is a major, potentially
preventable, adverse outcome. It is associated with
longer intensive care unit and hospital stays,4-8 increased
morbidity, including strokes/new central neurologic
events (incidence of 1.3%-1.7%4,9); and mortality (up to
5.6%-7.5% [RR, 1.7-3.4]4,6-8), as well as higher resource
utilization.6,10 The incidence of POAF varies widely based
on the intensity of surgical stress (Table 2, A4-8,11-19) and
patient characteristics (Table 2, B4-6,13,20-22). Some of the
risk factors for AF, such as hypertension, obesity, and
smoking, are modifiable, whereas others, such as older age,
Caucasian ancestry, and male sex are not. POAF peaks on
postoperative days 2 to 4, and 90% to 98% of new-onset
POAF resolves within 4 to 6 weeks.
The mechanisms of POAF are complex and require both
a vulnerable atrial substrate and a trigger to initiate AF
(Table 3). In the presence of a vulnerable substrate,
additional electrophysiologic abnormalities (drivers) will
sustain AF. As POAF is mostly limited to the first 4 to 6
weeks of the postoperative period, it is likely that inflamma-
tion related to surgery and healing contributes to POAF.The Journal of Thoracic and CaRECOMMENDATIONS
1. Recommend the Use of the Following Definitions
for the Diagnosis of POAF
Class I
1.1. Electrophysiologic definition/diagnosis: ECG record-
ings (1 or more ECG leads) that demonstrate the
presence of characteristic ECG features of AF
(Table 4) lasting at least for 30 seconds or for the
duration of the ECG recording (if shorter than
30 seconds)2,23 (level of evidence [LOE] C).
1.2. Clinical definition/diagnosis: clinically significant
POAF is AF in the (intra- and) postoperative setting
that requires treatment with rate or rhythm control
agents, or requires anticoagulation, and/or extends
the duration of hospitalization (LOE C). Clinical
symptoms may include hypotension, dizziness,
decreased urinary output, fatigue, and so on.
We recommend that both electrophysiologically
documented AF and clinically diagnosed AF be
included in the clinical documentation and reported
in clinical trials/studies.2. Physiologic (ECG) Monitoring of Patients at Risk
for POAF
Recommendations for the ECG monitoring of the
patients at risk for POAF are presented in Table 5.
Class I
2.1. Patients should be monitored with continuous ECG
telemetry postoperatively for 48 to 72 hours (or less
if their hospitalization is shorter) if:
2.1.1. They are undergoing procedures that pose
intermediate (5%-15% expected incidence of
AF) or high (>15%) risk (Table 2, A) for the
development of postoperative AF or have signifi-
cant additional risk factors (CHA2DS2-VASc2)
for stroke (LOE C).
2.1.2. They have a history of preexisting or periodic
recurrent AF before their surgery. These pa-
tients should also receive ECG monitoring in
the immediate preoperative period if proce-
dures (eg, epidural catheter or other regional
anesthesia blocks) are performed (LOE C).
Class IIa
2.2. Not using routine ECG telemetry is reasonable
for patients who undergo low-risk (<5% expected
incidence of AF) procedures, and have neither a
previous history of AF nor significant risk for stroke
(based on CHA2DS2-VASc score), and have no
relevant comorbidities (such as heart failure or
previous stroke) (LOE C).rdiovascular Surgery c Volume 148, Number 3 773
TABLE 1. Size of treatment effect and level of evidence for its impact
Schema used to guide the grading of available published evidence and the expected effect of the interventions for their impact on patient outcomes (the arrow indicates the
direction of increased effect size). COR, Class of recommendation.
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2.2.1. If patients exhibit clinical signs of possible AF
while not monitored with telemetry, ECG record-
ings to diagnose POAF and ongoing telemetry to
monitor the period of AF should be immediately
implemented (LOE C).
3. Rate Control and Antiarrhythmic Drugs,
Mechanism of Action, Side Effects and Limitations
A detailed description of the drugs used for the manage-
ment of rate (Table 6) or rhythm control (Table 724), their
mechanism of action, side effects, and limitations are
further discussed in the online document. Dosing informa-
tion is also presented in Tables 6 and 7.774 The Journal of Thoracic and Cardiovascular SurgClass IIa
3.1. To optimize the efficacy and safety of amiodarone, it is
reasonable to exercise caution when selecting its doses
or intravenous versus oral route, because cases of acute
respiratory distress syndrome (ARDS) have been re-
ported following pneumonectomy with cumulative
intravenous doses more than 2150 mg25 (LOE C).
4. Prevention Strategies and Their Efficacy
Recent evidence suggest that some prevention strategies
(avoiding b-blockade withdrawal for those chronically on
those medications, correction of serum magnesium when
abnormal) maybe effective for all patients for reducing
the incidence of POAF. By surveying the AATSery c September 2014
TABLE 2, A. Risk stratification of thoracic surgical procedures for their risk of POAF
Type of procedures
Risk of POAF by surgical procedures
Low-risk procedures
(<5% incidence)
Intermediate risk procedures
(5%-15% incidence)
High-risk procedures
(>15% incidence)
Intrathoracic/airway procedures
Minor procedures Flexible bronchoscopy with and
without biopsy
Photodynamic therapy
Tracheal stenting
Placement of thoracostomy tube or
PleurX catheter (CareFusion
Corporation, San Diego, Calif)
Pleuroscopy, pleurodesis, decortication
Procedures with
moderate stress
Tracheostomy
Rigid bronchoscopy
Mediastinoscopy
Thoracoscopic wedge resection5,6
Bronchoscopic laser surgery
Thoracoscopic sympathectomy
Major procedures Segmentectomy5,6 Resection of anterior mediastinal mass
Thoracoscopic lobectomy
Open thoracotomy for lobectomy4-6,12-15
Tracheal resection and reconstruction/carinal
resection
Pneumonectomy5,6,12,13,15-17
Pleurectomy11
Volume reduction/bullectomy
Bronchopleural fistula repair
Clagett window
Lung transplantation7,8,18
Esophageal procedures Esophagoscopy/PEG/esophageal dilation
and/or stenting
Laparoscopic Nissen
fundoplication/myotomy
Zenker diverticulectomy
Esophagectomy5,13,19
Other procedures Pericardial window
Thoracic surgical procedures were divided into low (<5%), moderate (5%-15%) and high (>15%) risk groups based on their expected incidence of POAF in order to facilitate
the preoperative risk stratification of patients. POAF, Postoperative atrial fibrillation; PEG, percutaneous endoscopic gastrostomy.
Frendl et al Clinical Guidelinesmembership, we also found that many of these strategies are
currently underused (Figure 1).
4.1. Recommended prevention strategies for all patients
Class I
4.1.1. Patients taking b-blockers before thoracic surgery
should continue them in the postoperative period
to avoid b-blockade withdrawal3,26-30 (LOE A).Cl
Cl
Class IIb
4.1.2. Intravenous magnesium supplementation may be
considered to prevent postoperativeAFwhen serum
magnesium level is low or it is suspected that total
body magnesium is depleted30-32 (LOE C).
ass III
4.1.3. Digoxin should not be used for prophylaxis
against AF2,23,33-35 (LOE A).
4.1.4. Catheter or surgical pulmonary vein isolation
(at the time of surgery) is not recommended for
prevention of POAF for patients who have no
previous history of AF36 (LOE C).The Journal of Thoracic and Ca4.1.5. Complete or partial pulmonary vein isolation
at the time of (even bilateral) lung surgery
should not be considered for prevention of
POAF, as it is unlikely to be effective36-38 (LOE
B).
For those patients at increased risk for the develop-
ment of POAF, preventive administration of
medications (diltiazem or amiodarone) may be
reasonable. However, these strategies may not be
useful for all thoracic surgical patients.
4.2. Recommended prevention strategies for intermedi-
ate to high-risk patientsrdass IIa
4.2.1. It is reasonable to administer diltiazem to those
patients with preserved cardiac function who are
not taking b-blockers preoperatively in order to
prevent POAF39,40 (LOE B).
4.2.2. It is reasonable to consider the postoperative
administration of amiodarone to reduce the inci-
dence of POAF for intermediate- and high-riskiovascular Surgery c Volume 148, Number 3 775
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TABLE 4. Recommended definitions for the diagnosis of POAF
Definitions COR
Electrophysiologic
definition/diagnosis
ECG recordings (1 or more ECG leads)
with ECG features of AF lasting at
least for 30 seconds or for the duration
of the ECG recording (if<30 seconds)
(LOE C)
I
Clinical
definition/diagnosis
Clinically significant POAF: intra- and
postoperative AF requiring treatment,
or anticoagulation, and/or extending
the duration of hospitalization (LOE C)
I
These measures should be included in the clinical documentation and reported in the
clinical trials/studies. POAF, Postoperative atrial fibrillation; ECG, electrocardiog-
raphy; COR, class of recommendation; LOE, level of evidence; AF, atrial fibrillation.
TABLE 2, B. Known patient risk factors for and comorbidities that
increase the risk of POAF
Risk factors and comorbidities Thoracic surgery references
Modifiable risk factors
Hypertension 4,13,20
MI 21
VHD
Heart failure 5,6,22
Obesity 4
Obstructive sleep apnea
Smoking
Exercise
Alcohol use
Hyperthyroidism
Increased pulse pressure
Mitral regurgitation
LVH
Increased LV wall thickness
Nonmodifiable risk factors
Increasing age 4-6,13,21,22
African American (protective factor) 4
Family history
Genetic variants
Male sex 4,5,13,22
History of arrhythmias 5,6
Derived from the 2014 American Heart Association Atrial Fibrillation Guidelines and
relevant literature for thoracic surgery. Patient risk factors and comorbidities that
were shown to increase the risk of atrial fibrillation (AF) are listed. Much of this in-
formation was extracted from the general population, thoracic surgery–specific refer-
ences are listed when available. These risk factors/comorbidities should be assessed
in conjunction with the procedure-related risks of AF in order to determine the true
risk of POAF. MI, Myocardial infarction; VHD, valvular heart disease; LV, left
ventricle; LVH, left ventricular hypertrophy.
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77patients undergoing pulmonary resection41-43
(LOE A).
ss IIb
4.2.3. Postoperative administration of intravenous
amiodarone may be considered to prevent
POAF in patients undergoing esophagectomy19
(LOE B).BLE 3. Probable mechanisms contributing to POAF
nically meaningful AF requires the presence of both a trigger and a
ulnerable atrial substrate
ial substrate changes that facilitate AF
ympathetic or parasympathetic stimulation
trial dilation or acute atrial stretch
ericarditis
ibrosis
nhomogeneous dispersion of conduction abnormalities
hort wavelength (conduction velocity 3 ERP)
ther (like inflammation and oxidative stress)
ddition, a driver(s) is thought to be needed to sustain AF in the
vulnerable substrate
apidly firing ectopic focus (atrial or other)
eentrant circuit(s) of short cycle length (ordered reentry)
otential role, if any, of multiple reentrant wavelets (random reentry)
Atrial fibrillation; ERP, effective refractory period.
6 The Journal of Thoracic and Cardiovascular Surg4.2.4. Atorvastatin may be considered to prevent
POAF for statin-naive patients scheduled for
intermediate- and high-risk thoracic surgical
procedures44-46 (LOE C).
4.3. Recommended prevention strategies for the
highest-risk patientsCla
Cla
eryss IIb
4.3.1. Left atrial appendage excision may be considered
at the time of extensive left lung surgery for pa-
tients with preexisting AF who are considered
too high a risk for anticoagulation in the perioper-
ative period2,23,47 (LOE C).5. Treatment Strategies for AF and Their Efficacy
The management of patients presenting with POAF re-
quires different strategies depending on their hemodynamic
stability. Although some interventions are likely to benefit
all patients (see section 5.1), hemodynamically unstable
patients will require urgent efforts for the restitution of
sinus rhythm (section 5.2). However, for stable patients
with POAF, the emphasis shifts to rate control strategies
(see details in section 5.3).
5.1. Management strategies recommended for all
patients with new-onset POAF (Figure 2)ss I
5.1.1. Reduce or stop catecholaminergic inotropic
agents if hemodynamics allow (LOE C).
5.1.2. Optimize fluid balance and maintain normal
electrolyte levels (LOE C).
5.1.3. Evaluate the presence of and treat all possible
correctable triggering factors. These may include
bleeding, pulmonary embolism, pneumothorax,
pericardial processes, airway issues, myocardial
ischemia, or infection/sepsis (LOE C).
ss IIb
5.1.4. Cardiology consultation may be useful for those
patients (LOE C) who:c September 2014
Cl
TABLE 5. Recommendations for physiologic (ECG) monitoring
Recommendations for monitoring COR
Patients should be monitored with continuous ECG telemetry
postoperatively for 48-72 h (or less if their hospitalization is
shorter) if:
 they are undergoing procedures that pose high (>15%
expected incidence of AF) or intermediate (5%-15%)
risk for POAF or
 they have significant additional risk factors (CHA2DS2-VASc
>2) for stroke (LOE C)
 they have a history of preexisting or periodic recurrent AF
before their surgery
These patients should also receive ECG monitoring in the
immediate preoperative period if procedures (epidural
catheter, regional anesthesia blocks, and so forth) are
performed (LOE C)
I
Not using routine ECG telemetry is reasonable for patients who
 undergo low risk surgery (<5% expected incidence
of AF) and
 had no previous history of AF, or
 have no significant risk for stroke and
 have no relevant comorbidities (eg, heart failure or previous
stroke) (LOE C)
IIa
If patients exhibit clinical signs of possible AF while not
monitored with ECG telemetry, ECG recordings to
diagnose POAF and continuous telemetry to monitor
the period of AF should be immediately implemented
(LOE C)
I
ECG, Electrocardiography; COR, class of recommendation; AF, atrial fibrillation;
POAF, postoperative atrial fibrillation; LOE, level of evidence.
Frendl et al Clinical Guidelines5.1.4.1. Develop recurrent or refractory POAF.
5.1.4.2. Develop a hemodynamically unstable
condition.
5.1.4.3. Are at high risk for stroke based on
CHA2DS2-VASc score and will likely
require longer-term anticoagulation.
5.1.4.4. Require a second-line antiarrhythmic
medication for stabilization.
5.1.4.5. Also develop acute kidney injury.5.2. Recommendations for the management of the
hemodynamically unstable patient with new-onset
POAF (Figure 3)ass I
5.2.1. Emergency R-wave synchronized direct current
(DC) electrical cardioversion is recommended
for hemodynamically unstable patients and for pa-
tients with evidence of acute myocardial ischemia
or infarction. Signs of hemodynamic instability
include: severe symptomatic hypotension, shock,
or pulmonary edema2,3,22,48 (LOE C).
5.2.1.1. For unstable patients with new-onset
POAF of less than 48-hours duration,
emergency DC cardioversion is indicatedThe Journal of Thoracic and Caand is acceptable before initiation of anti-
coagulation2,3 (LOE C).
5.2.1.2. For unstable patients who undergo car-
dioversion more than 48 hours after the
onset of AF, and who do not have an
excessive bleeding risk or other contrain-
dication, anticoagulation should be initi-
ated as soon as possible and continued for
at least 4 weeks2,3,49 (LOE C).
Class IIa
5.2.2. If initial DC cardioversion is unsuccessful or he-
modynamically unstable AF recurs, the following
steps can be useful:
5.2.2.1. Initiate rate and possible rhythm control
therapy with intravenous esmolol, diltia-
zem, digoxin, or amiodaronewhile prepar-
ing for repeat DC cardioversion (LOE C).
5.2.2.2. Repeat DC cardioversion (more likely to
be successful after initiating a rhythm
control agent) (LOE C).
5.3. Recommendations for the management of the
hemodynamically stable patient with new-onset
AF (Figures 4 and 5)
Primary treatment goal is rate control with rhythm
control as a secondary option.Class IIa
5.3.1. It is reasonable to manage stable, well-tolerated
new-onset POAF with a rate control strat-
egy2,30,50-52 (LOE C).
5.3.2. Rhythm control with antiarrhythmic drugs and/or
DC cardioversion can be useful for patients with
hemodynamically stable new-onset POAF who
have recurrent or refractory POAF, continued
symptoms, intolerance to rate control medica-
tions, or ventricular rates that cannot be
adequately controlled2,51,52 (LOE C).
5.3.3. A rhythm control approachwith pharmacologic or
DC cardioversion is reasonable for patients with
new-onset POAF nearing 48 hours in duration,
who are at high risk for bleeding, in order to avoid
anticoagulation that would be otherwise indicated
for AF persisting longer than 48 hours (LOE C).
5.4. Medical management of patients with new-onset
POAF (Figures 4 and 5)
5.4.1. Rate control recommendationsrdiovClass I
5.4.1.1. Intravenous administration of b-blockers
(eg, esmolol or metoprolol) or non–dihydro-
pyridine calcium channel blockers (diltia-
zem or verapamil) is recommended toascular Surgery c Volume 148, Number 3 777
CCl
Cl
Class
Class
TABLE 6. Commonly used rate control agents
Drug
Recommended
doses
Significant limitations
and known side effects
Diltiazem 0.25 mg/kg IV loading dose
over 2 min, then 5-15 mg/h
IV continuous infusion
Hypotension
Bradycardia
Heart failure
exacerbation
Digoxin 0.25 mg IV repeated every
2-4 h to a maximum dose
of 1.5 mg over 24 h
Nausea, vomiting,
anorexia
Confusion
AV block
Ventricular arrhythmias
Accumulates in acute
kidney injury/chronic
kidney disease
Esmolol 500 mg/kg IV bolus over 1 min,
then 50-300 mg/kg/min IV
continuous infusion
Bradycardia
Hypotension
Bronchospasm
Heart failure
exacerbation
Metoprolol 2.5-5.0 mg IV bolus over
2 min; maximum 3 doses
Bradycardia
Hypotension
Bronchospasm
Heart failure
exacerbation
Amiodarone 150-300 mg IVover 1 h,
followed by 10-50 mg/h IV
continuous infusion over 24 h
Bradycardia
QT interval prolongation
Pulmonary toxicity has
not been demonstrated
at this dose
Detailed information in section 3 of the online version of the guidelines and in
references 2 and 3. IV, Intravenous; AV, atrioventricular.
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778achieve rate control (heart rate 110 bpm)
for patients who develop POAF with rapid
ventricular response2,11,50 (LOE B).
5.4.1.1.1. Caution should be used with
patients with hypotension, left
ventricular (LV) dysfunction, or
heart failure2,11,23,50 (LOE B).
lass IIa
5.4.1.2. Combination use of atrioventricular (AV)
nodal blocking agents, such as b-blockers (eg,
esmolol or metoprolol), non–dihydropyridine
calcium channel antagonists (eg, diltiazem or
verapamil), or digoxin, can be useful to
control heart rates when a single agent fails to
control rates of POAF. The choice should be
individualized and doses modified to avoid
bradycardia2,23 (LOE B).
5.4.1.3. For patients with hypotension, heart failure, or
LV dysfunction, or when other measures are
unsuccessful or contraindicated, intravenous
amiodarone can be useful for control of heart
rate. Amiodarone could result in conversion
to sinus rhythm, and if it is initiated after 48The Journal of Thoracic and Cardiovascular Surgeryhours of AF, both transesophageal echocardi-
ography (TEE) when possible, to rule out left
atrial (LA)/left atrial appendage (LAA)
thrombus, and full anticoagulation should be
considered3,23,30,50,53 (LOE B).
ass IIb
5.4.1.4. For patients with heart failure, LV dysfunc-
tion or hypotension, intravenous digoxin
may be considered for rate control of
POAF23,30,54 (LOE B).
ass III
5.4.1.5. For patients with ventricular preexcitation (ie,
Wolff-Parkinson-White syndrome) andPOAF,
use of AV nodal blocking agents, such as
b-blockers (eg, esmolol or metoprolol), intra-
venous amiodarone, non–dihydropyridine
calcium channel antagonists (eg, diltiazem or
verapamil), or digoxin, should be avoided2,23
(LOE C).
5.4.2. Recommendations for the use of antiar-
rhythmic drugs (Figure 6, A and B)cIIa
5.4.2.1. Restoration of sinus rhythm with pharmaco-
logic cardioversion is reasonable in patients
with symptomatic, hemodynamically stable
POAF55-57 (LOE C).
5.4.2.1.1. Intravenous amiodarone can be use-
ful for pharmacologic cardioversion
of POAF7,30,50,53,58 (LOE B).
5.4.2.2. It is reasonable to administer antiarrhythmic
medications in an attempt to maintain sinus
rhythm for patients with recurrent or refractory
POAF2,59 (LOE B).
5.4.2.2.1. Amiodarone, sotalol, flecainide,
propafenone, or dofetilide can be
useful to maintain sinus rhythm
in patients with POAF, depending
on underlying heart disease, renal
status and other comorbidities
(see Table 7)2 (LOE B).
IIb
5.4.2.3. Flecainide or propafenone may be consid-
ered for pharmacologic cardioversion of
POAF and maintenance of sinus rhythm if
the patient has had no previous history of
myocardial infarction, coronary artery dis-
ease, impaired LV function, significant LV
hypertrophy, or valvular heart disease that
is considered moderate or greater. These
agents may need to be combined with an
AV nodal blocking agent58,60-64 (LOE C).September 2014
TABLE 7. Commonly used antiarrhythmic agents
Drug Recommended doses
Significant limitations and
known side effects Ref
Procainamide Conversion to sinus rhythm: 20-50 mg/min IV
continuous infusion until AF terminated,
hypotension occurs, or QRS duration
prolonged by 50%, or cumulative total dose of
15 mg/kg reached
Alternative dose: 100mg IVevery 5 min until AF
terminated or other conditions as listed above
are met
If available orally, could be used for maintenance
Hypotension
QT interval prolongation
Torsades de pointes
Contraindicated in patients with heart failure
with reduced left ventricular ejection fraction
Contraindicated in patients with pretreatment
QTc interval>470 ms (men) or 480 ms
(women)
24
Flecainide Conversion to sinus rhythm: 200-300 mg single
oral dose
Maintenance of sinus rhythm: 50-150 mg orally
once every 12 h
Dizziness
Blurred vision
Sinus bradycardia
AV block
Contraindicated in patients with heart failure
with reduced left ventricular ejection fraction
Contraindicated in patients with coronary artery
disease/structural heart disease
2,3
Propafenone Conversion to sinus rhythm: 450-600 mg single
oral dose
Maintenance of sinus rhythm: 150-300mg orally
every 8 h (immediate release); 225-425 mg
orally every 12 h (extended release)
Dizziness
Blurred vision
Sinus bradycardia
AV block
Contraindicated in patients with heart failure
with reduced left ventricular ejection fraction
Contraindicated in patients with coronary artery
disease/structural heart disease
2,3
Amiodarone Prophylaxis: 300 mg IV bolus, then 600 mg
orally twice daily for 3-5 d
Treatment: 150 mg IVover 10 min; then 1 mg/
min IV continuous infusion for 6 h; the 0.5
mg/min IV continuous infusion for 18 h or
change to oral administration at 100-400 mg
daily
Bradycardia
QT interval prolongation
Pulmonary toxicity has not been demonstrated at
this dose
Bradycardia
Hypotension
QT interval prolongation
Pulmonary toxicity has occurred at cumulative
IV doses>2150 mg in patients undergoing
pneumonectomy
2,3,41
Dofetilide Not ideal for conversion to sinus rhythm in the
postoperative setting; may take 2-3 d to
convert to normal sinus rhythm, which would
require commitment to anticoagulation
Maintenance of sinus rhythm: calculated CrCl
20-40 mL/min: 125 mg orally once every 12 h
Calculated CrCl 40-60 mL/min: 250 mg orally
once every 12 h
Calculated CrCl>60 mL/min: 500 mg orally
every 12 h
QT interval prolongation
Torsades de pointes
Risk of torsades de pointes is greater in patients
with heart failure
Dose adjustment is important in patients with
acute kidney injury or chronic kidney disease
Contraindicated in patients with calculated CrCl
<20 mL/min
Contraindicated in patients with pretreatment
QTc interval>470 ms (men) or 480 ms
(women)
Monitor ECGs 2 h after doses, telemetry for at
least 3 d
2,3
(Continued)
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TABLE 7. Continued
Drug Recommended doses
Significant limitations and
known side effects Ref
Ibutilide Conversion to sinus rhythm:
Weight 60 kg: 1 mg IV administered over
10 min
Weight<60 kg: 0.01 mg/kg IVadministered over
10 min
If the AF does not terminate within 10 min of
completion of the first infusion, a second dose
of equal strength may be administered IVover
10 min
Not indicated for maintenance of sinus rhythm
QT interval prolongation
Torsades de pointes
Risk of torsades de pointes greater in patients
with heart failure
Nonsustained ventricular tachycardia
Sinus pauses after AF conversion
Contraindicated in patients with pretreatment
QTc interval>470 ms (men) or 480 ms
(women)
Corvert prescribing information
2006; Pfizer, Inc
Sotalol Maintenance of sinus rhythm: 40-160 mg orally
every 12 h
Dosing interval should be adjusted in patients
with acute kidney injury or chronic kidney
disease:
If the calculated CrCl is 30-59
mL/min: administer every 24 h
If the calculated CrCl is 10-29
mL/min: administer every 36-48 h
Sinus bradycardia
AV block
QT interval prolongation
Torsades de pointes
Heart failure exacerbation
Risk of torsades de pointes greater in patients
with heart failure
Bronchospasm
Dose adjustment is important in patients with
acute kidney injury or chronic kidney disease
Use with extreme caution in patients with
calculated CrCl<10 mL/min and in patients
undergoing hemodialysis
Contraindicated in patients with pretreatment
QTc interval>470 ms (men) or 480 ms
(women)
2,3
IV, Intravenous; AF, atrial fibrillation; AV, atrioventricular; CrCl, creatinine clearance; ECG, electrocardiography.
FIGUR
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7805.4.2.4. Intravenous ibutilide or procainamide may be
considered for pharmacologic conversion of
POAF for patients with structural heart disease
and new-onset POAF, but no hypotension or
manifestations of congestive heart failure.E 1. Prevention strategies and their efficacy for postoperative atrial fibrillation (
nous; LVEF, left ventricular ejection fraction; AF, atrial fibrillation.
The Journal of Thoracic and Cardiovascular Surgery cSerum electrolytes and QTc interval must be
within a normal range and patients must be
closely monitored during and for at least 6
hours after the infusion if either ibutilide or pro-
cainamide61,65-68 (LOE B).POAF). LOE, Level of evidence;PVI, pulmonary vein isolation; i.v.,
September 2014
Class
Class
Class
FIGURE 2. Management algorithm for postoperative atrial fibrillation (POAF). AF, Atrial fibrillation;MI, myocardial infarction; HF, heart failure;WPW,
Wolff-Parkinson-White syndrome; DC, direct current; i.v./IV, intravenous; HR, heart rate; LV, left ventricular; COPD, chronic obstructive pulmonary dis-
ease; LA/LAA, left atrial/left atrial appendage; TEE, transesophageal echocardiography.
Frendl et al Clinical Guidelines5.4.2.5. Intravenous ibutilide or procainamide may
be considered for patients with POAF and
an accessory pathway2,23 (LOE B).
III
5.4.2.6. Flecainide and propafenone should not
be used to treat POAF in patients with a
history of a previous myocardial infarction,
coronary artery disease, and/or severe
structural heart disease, including severe
LV hypertrophy, or significantly reduced
LV ejection fraction3,69 (LOE B).
5.4.2.7. Dronedarone should not be used for
treatment of POAF in patients with heart
failure2,70 (LOE B).5.5. Nonpharmacologic management of POAF
5.5.1. Recommendations for DC cardioversion for
stable patients with POAF
I
5.5.1.1. DC cardioversion is recommended for symp-
tomatic or relatively hemodynamicallyThe Journal of Thoracic and Cardiovcompromised patients with POAF if they
do not respond promptly to pharmacologic
attempts to control rapid ventricular
rates2,3,49 (LOE C).
5.5.1.2. DC cardioversion is recommended for
patients without hemodynamic instability
when symptoms of AF are unacceptable to
the patient or when rapid ventricular rates
do not respond to pharmacologic measures2
(LOE C).
IIa
5.5.1.3. DC cardioversion can be a reasonable alter-
native to pharmacologic cardioversion55-57
(LOE C).
5.5.1.4. Pretreatment with an antiarrhythmic drug can
be useful to enhance the success ofDC cardio-
version (as described in section 5.2.2.1) and to
prevent recurrent AF2 (LOE B).
5.5.1.5. Caution is advised for patients with preopera-
tive or unknown sinus node dysfunction or
with patients receiving significant doses ofascular Surgery c Volume 148, Number 3 781
Cla
Cla
FIGURE 3. Management of the hemodynamically unstable patient with new-onset postoperative atrial fibrillation (POAF). AF, Atrial fibrillation; MI,
myocardial infarction; HF, heart failure; DC, direct current; i.v., intravenous; TEE, transesophageal echocardiography.
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782rate controlling medications, as significant
pauses can occur after DC cardioversion. For
those patients, external pacingmay be required
and should be readily available (LOE C).
5.5.1.6. It is reasonable to repeat DC cardioversion,
after administration of an antiarrhythmic
medication, for patients who relapse to AF
after successful cardioversion2,49 (LOE C).
5.5.1.7. Patient and physician preference are
reasonable considerations for selecting DC
cardioversion2 (LOE C).5.6. Recommendations for prevention of thromboem-
bolism for patients with stable AF/flutter undergo-
ing (DC or pharmacologic) cardioversion:ss I
5.6.1. For stable patients with POAF of 48 hours dura-
tion or longer, anticoagulation (with warfarin
for international normalized ratio [INR] 2.0-3.0,
an NOAC or low molecular weight heparinThe Journal of Thoracic and Cardiovascular Surgery[LMWH]) is recommended for at least 3 weeks
before and 4 weeks after cardioversion, regardless
of the method (electrical or pharmacologic) used
to restore sinus rhythm2 (LOE B).
ss IIa
5.6.2. During the first 48 hours after the onset of POAF,
the need for anticoagulation before and after DC
cardioversion may be based on the patient’s risk
of thromboembolism (CHA2DS2-VASc score;
Figures 9 and 10) balanced by the risk of
postoperative bleeding2 (LOE C).
5.6.3. For POAF lasting longer than 48 hours, as an
alternative to 3 weeks of therapeutic anticoagula-
tion before cardioversion of POAF, it is reasonable
to perform TEE in search of thrombus in the LA or
LAappendage, preferablywith full anticoagulation
at the time of TEE in anticipation of DC cardiover-
sion after the TEE71,72 (LOE B).
5.6.3.1. For patients with no identifiable
thrombus, DC cardioversion is reasonablec September 2014
Cla
FIGURE 4. Management of the hemodynamically stable patient with new-onset postoperative atrial fibrillation (POAF) of less than 48 hours duration.
WPW, Wolff-Parkinson-White syndrome; HR, heart rate; i.v., intravenous; HF, heart failure; LV, left ventricular; COPD, chronic obstructive pulmonary
disease; AF, atrial fibrillation; DC, direct current; TEE, transesophageal echocardiography.
Frendl et al Clinical Guidelinesimmediately after the TEE examination if
therapeutic anticoagulation is achieved.
Anticoagulation should continue for at
least 4 additional weeks although the ben-
efits must be weighed against the risk of
bleeding2,72 (LOE C).
5.6.4. For POAF lasting longer than 48 hours in pa-
tients who are not candidates for TEE (eg, af-
ter esophageal surgery), an initial rate control
strategy combined with therapeutic anticoagu-
lation using warfarin (aiming for INRThe Journal of Thoracic and Card2.0-3.0), a direct thrombin inhibitor (eg, dabi-
gatran), factor Xa inhibitor (eg, rivaroxaban,
apixaban), or LMWH is recommended for at
least 3 weeks before and 4 weeks after cardio-
version (LOE C).
5.6.5. Anticoagulation recommendations for cardiover-
sion of atrial flutter are similar to those for
AF2,3 (LOE C).
ss III
5.6.6. For patients with an identified thrombus,
cardioversion should not be performed until aiovascular Surgery c Volume 148, Number 3 783
Class
FIGURE 5. Management of the hemodynamically stable patient with new-onset postoperative atrial fibrillation (POAF) of more than 48 hours duration.
WPW, Wolff-Parkinson-White syndrome;HR, heart rate; i.v., intravenous; HF, heart failure; LV, left ventricular; COPD, chronic obstructive pulmonary dis-
ease; TEE, transesophageal echocardiography; LA/LAA, left atrial/left atrial appendage; DC, direct current; AF, atrial fibrillation.
Clinical Guidelines Frendl et allonger period of anticoagulation is achieved
(usually at least 3 weeks) and in accordance
with established AF guidelines2,71,72 (LOE B).
5.7. Recommendation for electrophysiology catheter
ablationCla
78ss III
5.7.1. Catheter or surgical ablation of AF is not
recommended for management of patients
with postoperative AF after thoracic surgery
(LOE C).4 The Journal of Thoracic and Cardiovascular Surg5.8. Surgical and interventional treatment options
5.8.1. Recommendations for preexisting AFery cI
5.8.1.1. Preexisting AF should be managed
according to existing guidelines for non–
postoperative AF (see section 6).6. Management of the Patient With Preexisting AF
Patients with preexisting AF represent a high-risk popu-
lation for stroke, heart failure, and other POAF-related com-
plications. Some may present with valvular heart disease.
The management of their antiarrhythmic medications, andSeptember 2014
FIGURE 6. A, Antiarrhythmic drugs recommended for pharmacologic
cardioversion of postoperative atrial fibrillation (POAF). B, Antiar-
rhythmic drugs recommended for maintenance of sinus rhythm after car-
dioversion of POAF. MI, Myocardial infarction; CAD, coronary artery
disease; LV, left ventricular; AV, atrioventricular; CHF, congestive heart
failure; HF, heart failure.
Frendl et al Clinical Guidelinestheir perioperative anticoagulation may pose a challenge
(Figure 7).
6.1. Criteria for obtaining cardiology consult for preop-
erative AFClass IIa
6.1.1. Preoperative cardiology consult can be useful
for patientswith preoperativeAF that is either newly
diagnosed or persistent and symptomatic (LOE C).
6.2. Perioperative management of anticoagulation for
patients on long-term (warfarin or NOAC) anticoa-
gulation.Class I
6.2.1. Decisions regarding the duration of interruption
of anticoagulation and/or the need for periopera-
tive heparin bridging should be based on the
patient’s stroke risk profile (based on their
CHA2DS2-VASc score) (LOE C).The Journal of Thoracic and CaClass IIa
6.2.2. For patients who have a high stroke risk (based
on their CHA2DS2-VASc score (Figures 9
and 10), history of previous stroke, or presence of
a mechanical heart valve, perioperative bridging
with a short-acting anticoagulant (ie, enoxaparin)
is reasonable for patients with estimated glomer-
ular filtration rate greater than 50%when warfarin
anticoagulation is withheld (LOE C).
Class IIb
6.2.3. Short-term withdrawal of anticoagulation without
bridging may be considered for those patients
who are on anticoagulation preoperatively as
part of their treatment for persistent AF but have
a CHA2DS2-VASc score less than 2, have not
had heart failure, have an ejection fraction
greater than 35%, and/or for whom bridging anti-
coagulation would be burdensome or otherwise
undesirable (LOE C).
6.3. Postoperative resumption of anticoagulation
Class IIa
6.3.1. If anticoagulation is interrupted, the duration
should be minimized. It is reasonable to base
decisions about the duration of interruption and
the time of resumption of anticoagulation on the
patient’s stroke risk profile (CHA2DS2-VASc
score) weighed against the risk of postoperative
bleeding (LOE C).
6.4. Postoperative follow-up
Class IIb
6.4.1. It is reasonable to consider postoperative follow-
up with a cardiology specialist for patients with
preoperatively identified AF who meet 1 or
more of the following criteria:
6.4.1.1. Ejection fraction 45% or less or diagnosis
of systolic heart failure or cardiomyopathy
6.4.1.2. Discharged on a new rate control and/or
rhythm control agent(s)
6.4.1.3. Dose of a home rhythm control agent(s)
was adjusted while an inpatient
6.4.1.4. Discharged on a new anticoagulant
(parenteral and/or oral) (LOE C)
7. Management of Anticoagulation for New-Onset
POAF
In order to minimize the risk of perioperative
bleeding while providing sufficient protection from the
POAF-related strokes, a careful evaluation of the patients’
stroke risk is essential. The recently approved novel oral an-
ticoagulants (NOAC; direct thrombin inhibitors and anti-
Factor Xa agents) offer alternatives to warfarin, and arerdiovascular Surgery c Volume 148, Number 3 785
FIGURE 7. Algorithm for the management of patients with preoperative atrial fibrillation (AF). Preop, Preoperative; CHF, congestive heart failure; SOB,
shortness of breath; EF, ejection fraction.
Clinical Guidelines Frendl et algaining popularity in the community for the long-termman-
agement of AF-related anticoagulation.
Class I
7.1. For the prevention of strokes for patients who develop
POAF lasting longer than 48 hours, it is recommended
that antithrombotic medications are administered
similarly to nonsurgical patients (Figure 8). The deci-
sion to initiate therapy should be based on the benefit
of reducing stroke risk versus the risk of bleeding in
the postoperative period49,73-75 (LOE A).
7.1.1. For effective anticoagulation, an INR range of
2 to 3 (with a target of 2.5) for warfarin is
recommended unless otherwise contraindi-
cated76,77 (LOE A).
7.1.2. The INR should be determined at least weekly
during initiation of therapy and monthly when
the doses of anticoagulant and the INR are sta-
ble78-80 (LOE A).
7.2. Anticoagulation within the first 48 hours of POAF
(Figure 9) should be considered based on the
CHA2DS2-VASc risk score (Figure 10) of the patient
for stroke weighed against the risk of postoperative
bleeding (LOE C).
7.2.1. For risk assessment, the following may serve as a
guide: CHA2DS2-VASc risk score (Figure 10)
for stroke2,65 (LOE A):786 The Journal of Thoracic and Cardiovascular SurgS ¼ 0: no anticoagulation recommended
S¼ 1: anticoagulation should be considered if its
benefits outweigh the risk of bleeding
S¼ 2: anticoagulation is highly recommended if
its benefits outweigh the risk of bleeding
7.2.2. The presence of impaired renal function should
weigh in favor of anticoagulation. Caution
should be exercised when patients on dialysis are
considered for anticoagulation because the benefits
for those patients are less certain2,3,81-84 (LOE A).
7.2.3. If not precluded by concerns for bleeding, anti-
coagulation is also recommended when conver-
sion to sinus rhythm is attempted by (DC or
chemical) cardioversion (see section
5.6)2,3,49,74,75 (LOE C).
Class IIa
7.3. New oral anticoagulants (dabigatran, rivaroxiban,
apixiban85-88) are reasonable as an alternative to
warfarin (Table 8) for patients who do not have a
prosthetic heart valve, hemodynamically significant
valve disease, and/or severe renal impairment or risk
of gastrointestinal bleeding2,89-91 (LOE B).
7.4. It is reasonable to continue anticoagulation therapy for
4 weeks after the return of sinus rhythm because of the
possibility of slowly resolving impairment of atrial
contraction with an associated ongoing risk forery c September 2014
FIGURE 8. Management of anticoagulation for postoperative atrial fibrillation (POAF) lasting longer than 48 hours. NOACs, New oral anticoagulants;
INR, international normalized ratio.
Frendl et al Clinical Guidelinesthrombus formation and for delayed embolic
events49,74,75 (LOE C).
Class III
7.5. New oral anticoagulants should be avoided for patients
at risk for serious bleeding (including gastrointestinal
bleeding) as they cannot be readily reversed. However,
their use may be recommended in situations where
achievement of a therapeutic INR with warfarin has
proved to be difficult92 (LOE C).FIGURE 9. Considerations for the management of anticoagulation within
the first 48 hours of postoperative atrial fibrillation (POAF).
The Journal of Thoracic and Ca8. Recommendations for Long-Term Management
and Follow-up of PatientsWith Persistent New-Onset
POAF
Those patients with POAF-related perioperative
complications, and those requiring long-term management of
antiarrhythmics and anticoagulants are likely to benefit from
cardiology follow-up after their discharge (Figure 11).
8.1. Postdischarge follow-up and management recom-
mendations for persistent new-onset POAF:Class I
8.1.1. For patients who have a complicated in-hospital
course related to their POAF, who have underlying
structural heart disease, or who experience sequelae
of AF, such as myocardial infarction or decreased
LV ejection fraction, follow-up with cardiology
should be arranged at the timeof discharge (LOEC).
Class IIb
8.1.2. Patients with well-controlled new-onset POAF
(either converted to sinus rhythm or with good rate
control)maybe seen in routine follow-up by the sur-
gical team without cardiology follow-up (LOE C).
8.2. Management of antiarrhythmic medications
Cl
rdass IIa
8.2.1. For patients who have converted to sinus rhythm
before hospital discharge, it is reasonable toiovascular Surgery c Volume 148, Number 3 787
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FIGURE 10. Stroke risk stratification in atrial fibrillation. From: Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification
for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest.
2010;137:263-72. HTN, Hypertension; MI, myocardial infarction; PAD, peripheral arterial disease.
Clinical Guidelines Frendl et alconsider discontinuation of antiarrhythmic medica-
tions 4 weeks after ECG documented return of
normal sinus rhythmor at thefirst postoperativevisit
(usually 2-6 weeks after discharge) (LOE C).
Class IIb
8.2.2. For patients with new-onset POAF who were
discharged in AF but who are in normal sinus
rhythm (ECG confirmed) at the first postoperative
visit, it may be reasonable to instruct the patients
to self discontinue the antiarrhythmic medica-
tions 4 weeks after the visit if no signs of AF recur
(LOE C).
8.3. Management of anticoagulation
Cla
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8.3.1. For patients who are started on anticoagulants, the
anticoagulation should continue for a minimum
of 4 weeks after return to normal sinus rhythm
is documented (LOE C).BLE 8. Commonly used anticoagulants
Drug Mechanism
Half
life (h) Mode of clearance Recomm
rfarin Vitamin K
antagonist
Up to 40 Hepatically
metabolized
Variable (monit
igatran Thrombin
inhibitor
13 Renal 150 mg twice a
day for CrCl
aroxaban Factor Xa
inhibitor
7-11 Renal/hepatobiliary 20 mg daily, 15
50 mL/min
ixaban Factor Xa
inhibitor
12.7 Renal/fecal 5 mg twice a da
(AF) for at le
age>80 y, bo
>1.5 mg/dL
, International normalized ratio; CrCl, creatinine clearance; P-gp, P-glycoprotein; CYP3A
8 The Journal of Thoracic and Cardiovascular Surgeryss IIa
8.3.2. More prolonged anticoagulation (longer than 4
weeks after return to normal sinus rhythm) can be
beneficial in the presence of stroke risk factors
(CHA2DS2-VASc score) or if the patient had a pre-
vious stroke. The concomitant presence of mild or
moderately impaired kidney function weighs in
favor of a longer period of anticoagulation (LOEB).8.4. Recommendations for long-term management of
new-onset persistent POAFss IIa
8.4.1. Patients with new-onset POAF persisting for or
recurring after 4 to 6 weeks (or at the time
of the first postoperative visit) can benefit
from referral to a cardiologist for long-term
management of stroke risk as well as antiar-
rhythmic or anticoagulant medications (LOE C).ended doses Significant limitations Ref
or INR) Multiple food and drug interactions,
need for frequent INR monitoring
and dose adjustments
2,3,65
day; 75 mg twice a
30-50 mL/min
Interaction with inhibitors of P-gp, no
established antidote, not
recommended in severe renal
failure
2,3,81
mg daily for CrCl 15- Interaction with inhibitors of P-gp
and CYP3A4, no established
antidote, not recommended in
severe renal failure
2,3,82
y; 2.5 mg twice a day
ast 2 of the following:
dy weight<60 kg, Cr
Interaction with inhibitors of P-gp
and CYP3A4, no established
antidote, not recommended in
severe renal failure
2,3,82
4, cytochrome P450 3A4; AF, atrial fibrillation; Cr, serum creatinine.
c September 2014
FIGURE 11. Recommendation for the postdischarge follow-up for patient with new-onset postoperative atrial fibrillation (POAF). Post-op, Postoperative;
EF, ejection fraction; NSR, normal sinus rhythm; ECG, electrocardiography.
Frendl et al Clinical GuidelinesRECOMMENDATIONS FOR FUTURE AATS
EFFORTS
We recommend the establishment of a high-fidelity thoracic
surgery database that uses the uniform definitions and moni-
toring strategies recommended here, stratifies patients by sur-
gery type, and systematically documents the occurrence,
duration, and complications of POAF and its treatment. The
aim would be to develop risk prediction models and
eventually randomized interventional trials for the prevention
and treatment of POAF, specific to thoracic surgery. This could
be most readily accomplished by enriching the Society of
Thoracic Surgeons (STS) data collection system.
These guidelines are best used as a guide for practice and
teaching.The applicabilityof these recommendations to the in-
dividual patient should be evaluated on a case-by-case basis,
andonly appliedwhen clinically appropriate. In addition, these
guidelines can serve as a tool for uniform practices, to guide
preoperative evaluations, and form the basis of large, multi-
center cohort studies for the thoracic surgical community.
The task force received no financial support. AATS
provided teleconferencing and covered the cost of a 1-dayThe Journal of Thoracic and Caface-to-face conference for the participants. The members
of this taskforce had no conflicts of interest related to any
of the 88 recommendations made here; all their other
potential conflicts of interest were disclosed in writing
(Online Data Supplement 2).
A full-length copy of the detailed guidelines can be found
as an online publication93 at www.jtcvs.org.
A heartfelt thank you goes to Mr James M Bell for his artistic
contribution in finalizing the figures and tables as well as to
Mr Matt Eaton (AATS) for his role in coordinating all task force
meetings and activities.References
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